Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexigen Therapeutics has said that a notice of allowance has been issued by the US Patent and Trademark Office for a patent application providing broad coverage of the use of zonisamide either alone or in combination with other drugs in the treatment of obesity.
Subscribe to our email newsletter
This patent, when issued, would complement an issued US patent that covers zonisamide to promote weight-loss in combination with bupropion. Both patents would expire in 2023.
Gary Tomlinson, Orexigen’s president and CEO, said: “We believe this strengthens our intellectual property rights with Emphatic (zonisamide sustained release (SR) paired with bupropion SR), and may block attempts to copy our approach to treating obesity with any zonisamide-based compounds.”